25 May 2013
Keywords: UCB, Lectus Theapeutics, CNS portfolio
Article | 23 November 2011
Belgian drugmaker UCB (Euronext Brussels: UCB) has acquired the key pharmaceutical assets of closely-held, UK based drug developer Lectus Therapeutics ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 November 2011
22 November 2011
24 May 2013
© 2013 thepharmaletter.com